A $2.88 Billion Reason Why Eli Lilly Stock Is in Focus Today

Eli Lilly (LLY) shares are in the spotlight on Monday after the pharmaceutical behemoth announced a $2.88 billion acquisition of Merida Biosciences. The all-cash acquisition of the biotechnology company marks LLY’s latest move to expand its drug pipeline. 

Note that Eli Lilly stock has been a blockbuster investment in recent months, currently up roughly 35% versus its year-to-date low in late April. 

What Merida Acquisition Means for Eli Lilly Stock

Lilly’s agreement to acquire Merida Biosciences signals the giant’s commitment to strengthening its dominance beyond cardiometabolic care.

By bringing Merida’s novel clinical-stage assets targeting allergic and autoimmune disorders under its umbrella, Eli Lilly is adding long-term pipeline depth without sacrificing operational focus.

While upfront acquisition and integration costs could weigh on near-term profits, the deal is bullish for LLY shares as it reinforces the firm’s commitment to reinvesting its massive cash reserves into high-upside innovations, ensuring longer-term revenue growth. 

Note that Barchart also currently holds a “64% BUY” opinion on Eli Lilly, which means technical momentum is also in favor of the pharma giant for the remainder of 2026. 

Do LLY Shares Justify Their Premium Multiple?

Eli Lilly shares have pulled back in recent sessions and are now trading at a forward price-to-earnings (P/E) multiple of about 32x. 

Although that still looks stretched for a healthcare company, LLY continues to deliver phenomenal results, posting a year-over-year increase of 48% in its Q2 revenue on blockbuster Mounjaro and Zepbound sales. 

Management also raised its full-year guidance recently to at least $85 billion in revenue, which makes Lilly even more attractive as a long-term holding. 

It's also worth mentioning that the pharmaceutical behemoth currently pays a dividend yield of 0.6%, making it a compelling buy for income-focused investors. 

Wall Street’s View on Eli Lilly

Despite LLY stock’s solid year-to-date performance, Wall Street analysts believe its rally is not out of steam just yet.

According to Barchart, the consensus rating on Eli Lilly remains at “Strong Buy,” with the mean price target of about $1,335 indicating potential upside of nearly 15% from current levels.